<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2946">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345887</url>
  </required_header>
  <id_info>
    <org_study_id>10042020</org_study_id>
    <nct_id>NCT04345887</nct_id>
  </id_info>
  <brief_title>Spironolactone in Covid-19 Induced ARDS</brief_title>
  <official_title>The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University-Cerrahpasa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University-Cerrahpasa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intended to evaluate the effects of commonly used diuretic, spironolactone, on
      oxygenation in covid-19 ARDS patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 21, 2020</start_date>
  <completion_date type="Anticipated">October 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 21, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>p/f ratio</measure>
    <time_frame>5 days</time_frame>
    <description>improvement in oxygenation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOFA</measure>
    <time_frame>5 days</time_frame>
    <description>improvement in SOFA Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>Spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 x 100 mg spironolactone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x 1 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 100mg</intervention_name>
    <description>2x100 mg spironolactone for 5 consecutive days</description>
    <arm_group_label>Spironolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>2 x1 placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodynamically stable

          -  Hypoxemia, i.e. p/f &lt;150

          -  Admitted to ICU within 48 hours

          -  Not moribund has a life expectancy greater than 24 hours

        Exclusion Criteria:

          -  Age criteria

          -  Pregnancy

          -  Unwillingness to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yalim Dikmen</last_name>
    <role>Study Director</role>
    <affiliation>Prof</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olcay Dilken</last_name>
    <phone>+905547378709</phone>
    <email>olcaydilken@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul University-Cerrahpaşa</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Olcay Dilken</last_name>
      <phone>+905547378709</phone>
      <email>olcaydilken@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.</citation>
    <PMID>32227760</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University-Cerrahpasa</investigator_affiliation>
    <investigator_full_name>Olcay Dilken</investigator_full_name>
    <investigator_title>Araş. Gör.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

